A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Description

This study will collect biospecimens (including blood, tissue, and stool samples) and health information to create a database-a type of collection of information-for better understanding young onset colorectal cancer (YOCRC). The study will include both people with YOCRC and healthy people.

Conditions

Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will collect biospecimens (including blood, tissue, and stool samples) and health information to create a database-a type of collection of information-for better understanding young onset colorectal cancer (YOCRC). The study will include both people with YOCRC and healthy people.

Investigation of the Potential Effects of Pharmacologic Agents on Young Onset- Colorectal Cancer

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-49 years old
  • * Histological or cytological diagnosis of colorectal adenocarcinoma
  • * Planned CRC resection biopsy, or colonoscopy ,including surveillance colonoscopies and/or have already undergone prior surgical resection, with tissue, including normal colonic mucosae distant from the malignant tumor (only patients providing tissue sample)
  • * Enrollment in IRB# 20-315, Young Onset Gastrointestinal Cancer Prospective Registry (Andrea Cercek, PI)
  • * 18-49 years old at time of diagnosis
  • * Scheduled for standard-of-care colonoscopy at MSK
  • * CRC Cohort:
  • * Antibiotic use within 6 months of collection of stool for gut microbiome analysis s (only patients providing stool sample)
  • * Known inherited cancer susceptibility gene
  • * History of inflammatory bowel disease
  • * Antibiotic use within 6 months of collection of stool for gut microbiome analysis (only patients providing stool sample)
  • * History of or prior treatment for cancer ≤ 5 years prior to registration. Exceptions include non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.
  • * Colonoscopy for indications of IBD, anemia and/or genetic predisposition (only patients providing tissue sample).

Ages Eligible for Study

18 Years to 49 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Andrea Cercek, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-09